The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
918
March 18, 1994
View Complete Issue         Table of Contents 2019 
Lodoxamide for Vernal Keratoconjunctivitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lodoxamide for Vernal Keratoconjunctivitis
March 18, 1994 (Issue: 918)
Lodoxamide, a mast cell stabilizer, has been marketed in a 0.1% ophthalmic solution (Alomide - Alcon) for treatment of vernal keratoconjunctivitis.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lodoxamide for Vernal Keratoconjunctivitis
Article code: 918c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.